Awareness of metabolic concerns and perceived impact of pharmacotherapy in patients with bipolar disorder: A survey of 500 US psychiatrists

Department of Psychiatry, Bipolar Disorder Research Program, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9121, USA.
Psychopharmacology bulletin (Impact Factor: 0.5). 01/2007; 40(2):22-37; quiz 38-40.
Source: PubMed


An online survey was conducted to assess psychiatrists' familiarity with the metabolic syndrome and its components in patients with bipolar disorder, and characterize their perspectives and practices regarding its impact on patient management.
Participants were US psychiatrists from a random sample of those in the AMA database. Qualified respondents practiced 4-30 years, spent > or = 50% of their time in direct patient care, and treated > or = 25 bipolar patients in the last month. Results were collected and tabulated by Harris Interactive from Nov-Dec 2005.
Five hundred psychiatrists qualified and completed the survey, and 50 respondents also participated in follow-up interviews. Most respondents (94%) viewed metabolic syndrome as a significant health risk requiring monitoring and treatment. While 76% have diagnosed it, only 28% correctly identified the five NCEP diagnostic criteria. Medication adverse effects of greatest concern were weight gain, glucose intolerance, and dyslipidemia. During treatment, 78% of respondents reported monitoring weight, 69% glucose, 61% lipids, and 52% blood pressure. Most respondents (92%) reported referring patients to specialists or primary care for metabolic abnormalities. Changes in metabolic profile were reported to prompt many psychiatrists (85%) to stop or switch bipolar medications, especially those who treat a large number of bipolar patients (89%). The follow-up interviews supported a change in practice patterns over the last 5 years.
Nearly all respondents have metabolic concerns with medical therapies used to treat bipolar disorder. Many now routinely monitor weight and other metabolic parameters. Most have referred patients for medical management and adjusted bipolar therapies due to metabolic abnormalities.

Download full-text


Available from: Susan L Mcelroy,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Obesity is highly prevalent in persons with bipolar disorder. This results in increased physical morbidity and poorer psychiatric outcomes. Multiple variables have been identified as potentially responsible for the weight gain in these individuals. Efforts to use successful treatment strategies require an understanding of these variables and methods that clinicians and their clients can use to reduce or minimize these risk factors. This article will review the emerging findings related to primary and secondary weight gain in bipolar disorder. The sequelae of weight gain on psychiatric and medical morbidity will be discussed. Lastly, a model for nursing assessment will propose methods for modifying risk factors and encouraging healthy lifestyle changes. The goal is to improve this component of quality of life for persons with bipolar disorder. J Am Psychiatr Nurses Assoc, 2008; 13(6), 345-352. DOI: 10.1177/1078390307310145.
    Journal of the American Psychiatric Nurses Association 12/2008; 13(6):345-52. DOI:10.1177/10783903080130060401 · 0.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the December 2007 issue of the Bulletin, Suppes et al. reported the results of an online physician survey, regarding their awareness of metabolic concerns in patients with bipolar disorder.1 They reported results from 500 psychiatrist respondents, ranging from awareness of metabolic syndrome to metabolic monitoring pre- and postmedication treatment. Of special interest is the finding that 57% responded as having performed a fasting or nonfasting plasma glucose at baseline, while 69% reported monitoring fasting or nonfasting plasma glucose during treatment.
    Psychopharmacology bulletin 02/2008; 41(2):5-6; author reply 7-8. · 0.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An online survey of European psychiatrists assessed awareness of the metabolic syndrome and its influence on the management of bipolar disorder. Psychiatrists in the United Kingdom, France, Germany, Spain, and Italy were surveyed from April to June 2006. Eligibility criteria w ere 4-30 years in practice, >or=50% of time in direct patient care, had seen >or=10 bipolar patients in the preceding month. Aggregate data were weighted to represent the practicing physician population per country. Of 718 respondents, 56% had diagnosed metabolic syndrome. Respondents reported that metabolic syndrome prevalence was higher in bipolar patients (25%) than in the general population (20%). Seventy-two percent felt that metabolic syndrome poses significant health risks, warranting monitoring/treatment, and were most concerned with the bipolar medication adverse effects of weight gain, cognitive impairment, and glucose intolerance. Survey respondents recognized clear differences among psychotropic agents in the propensity to induce metabolic adverse effects. Sixty-five percent of respondents indicated that they had made interviewing and monitoring changes in the past three years as a result of metabolic concerns. European psychiatrists view metabolic syndrome as highly prevalent in the general population and in bipolar patients; two-thirds have changed their management of bipolar patients because of metabolic health concerns.
    European Psychiatry 05/2008; 23(3):169-77. DOI:10.1016/j.eurpsy.2007.10.007 · 3.44 Impact Factor
Show more